NasdaqGS:ARQTBiotechs
Patient Survey on Steroid Concerns Could Be A Game Changer For Arcutis Biotherapeutics (ARQT)
In January 2026, Arcutis Biotherapeutics released results from its nationwide Skin Insights survey, revealing how adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis view topical steroid use and disease management.
The findings point to a widespread reliance on reactive, flare-focused care and high concern about steroid side effects, highlighting interest in longer-term, non-steroidal treatment approaches.
We’ll now examine how this emphasis on...